Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
168 Results for "
GLP-1R
" in MedChemExpress (MCE) Product Catalog:
Products (168)
168 Results for "GLP-1R" in MCE Product Catalog:
50
50 Publications Verification
Research Areas:
50
50 Publications Verification
Research Areas:
50
50 Publications Verification
Cat. No.: HY-114118A
Purity: 99.92%
Research Areas:
46
Target:
Exendin (9-39) amide (Avexitide) is a competitive GLP-1R antagonist. Exendin (9-39) amide blocks the Semaglutide (HY-114118)-induced increase in insulin secretion and also attenuates the hypoglycemic effect of Semaglutide. Exendin (9-39) amide abolishes the islet-protective effect of Liraglutide. Exendin (9-39) amide can be used in research on type 2 diabetes and type 1 diabetes [1] .
46
Target:
Research Areas:
Exendin (9-39) amide acetate (Avexitide acetate) is a competitive GLP-1R antagonist. Exendin (9-39) amide acetate blocks the Semaglutide (HY-114118)-induced increase in insulin secretion and also attenuates the hypoglycemic effect of Semaglutide. Exendin (9-39) amide acetate abolishes the islet-protective effect of Liraglutide. Exendin (9-39) amide acetate can be used in research on type 2 diabetes and type 1 diabetes [1] .
7
7 Cited Publications
Target:
Research Areas:
GLP-1R Antagonist 1 (compound 5d) is an orally active, CNS penetrant and non-competitive antagonist of glucagon-like peptide 1 receptor (GLP-1R), with an IC50 of 650 nM [1].
4
Target:
Research Areas:
Danuglipron (PF-06882961) is an orally active glucagon-like peptide-1 receptor (GLP-1R) agonist. Danuglipron has the potential for type 2 diabetes research [1] .
3
Target:
Research Areas:
3
3 Cited Publications
Synonyms: LY3502970; GLP-1 receptor agonist 1
Target:
Research Areas:
Orforglipron (LY3502970) (Compound 67) is an orally active agonist for Glucagon-like peptide-1 receptor (GLP-1R), which exhibits potency in ameliorates the type 2 diabete [1].
3
Target:
Research Areas:
3
3 Cited Publications
Synonyms: LY3502970 hemicalcium hydrate; GLP-1 receptor agonist 1 hemicalcium hydrate
Target:
Research Areas:
Orforglipron hemicalcium hydrate (LY3502970 hemicalcium hydrate; GLP-1 receptor agonist 1 hemicalcium hydrate) is the calcium salt hydrate form of Orforglipron (HY-112185). Orforglipron is an orally active agonist for Glucagon-like peptide-1 receptor (GLP-1R), which exhibits potency in ameliorating the type 2 diabete [1].
3
Target:
Research Areas:
2
2 Cited Publications
Cat. No.: HY-P81160
Synonyms: Glucagon like peptide-1 receptor; GLP 1 R; GLP 1 receptor; GLP 1R; GLP1R; GLP; GLP1R; Glucagon like peptide 1 receptor; RATGL1RCP; Glip; MGC138331; GLP-1-R; GLP1R_HUMAN; Glucagon-like peptide 1 receptor; GLP-1 receptor; GLP-1-R; GLP-1R; Precursor.
2
2 Cited Publications
Cat. No.: HY-P700468
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: GLP1R; GLP-1-R; Glucagon Like Peptide 1 Receptor; Seven Transmembrane Helix Receptor; Glucagon-Like Peptide 1 Receptor; GLP1 Receptor; GLP-1R; GLP-1; GLP-1 Receptor
Species:
Human
Source:
HEK293
1
1 Cited Publications
Cat. No.: HY-P72206
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: GLP1R; GLP-1-R; Glucagon Like Peptide 1 Receptor; Seven Transmembrane Helix Receptor; Glucagon-Like Peptide 1 Receptor; GLP1 Receptor; GLP-1R; GLP-1; GLP-1 Receptor
Species:
Mouse
Source:
E. coli
1
Target:
Research Areas:
Target:
Research Areas:
GLP-1R agonist 2 (compound 2) is an effective GLP-1R agonist that exerts its activating effect by forming hydrogen bonds with the Tyr42, Cys71, and Ser84 residues of GLP-1R. GLP-1R agonist 2 has the potential for research in metabolic diseases such as type 2 diabetes and obesity [1].
Cat. No.: HY-160734
CAS No.: 2685823-26-9
Synonyms: GSBR-1290
Target:
Research Areas:
Aleniglipron (GSBR-1290) is an orally active glucagon-like peptide-1 receptor (GLP-1R) agonist, with an EC50 value of less than 0.1 nM in HDB cell lines in cAMP stimulation assays. Aleniglipron selectively activates the Gαs-cAMP signaling pathway of GLP-1R without β-arrestin recruitment. Aleniglipron induces insulin release, promotes glucose clearance, reduces food intake and decreases body weight. Aleniglipron is applicable to research related to type 2 diabetes and obesity [1] .
Cat. No.: HY-177295
CAS No.: 2572566-11-9
Synonyms: LY3549492
Target:
Research Areas:
Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Naperiglipron (LY3549492) is an orally active Glucagon-like peptide 1 receptor (GLP-1R) agonist with an EC50 of 1.14 nM for hGLP-1R. Naperiglipron significantly decreases the level of blood glucose in GLP-1R knock-in mouse models. Naperiglipron inhibits PDE10A1 enzyme activity (IC50: 7.43 μM) with a weak hERG inhibitory activity. Naperiglipron can be used for type II diabetes mellitus (T2DM) and obesity research [1].
Cat. No.: HY-P10302A
Target:
Research Areas:
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
